Today announced positive top-line outcomes from a pivotal.

Advanced Life Sciences Holdings’ Restanza promising against tularemia Advanced Existence Sciences Holdings, Inc. , today announced positive top-line outcomes from a pivotal, nonhuman primate research of its novel, once-a-day, oral antibiotic Restanza against an inhaled lethal dose of tularemia. A 14-day span of Restanza accomplished a 100 percent survival rate at the doses tested. All the ten animals in the analysis that received 16 mg/kg once-a-day of Restanza within a day after exposure to a lethal dosage of inhaled tularemia survived while only 1 of the ten pets that received placebo survived.Maki, M.D., Ph.D., Sai-Hong I. Ou, M.D., Ph.D., Bruce J. Dezube, M.D., Pasi A.D., Ph.D., Daniel B. Costa, M.D., Ph.D., Marileila Varella-Garcia, Ph.D., Woo-Ho Kim, M.D., Thomas J. Lynch, M.D., Panos Fidias, M.D., Hannah Stubbs, M.S., Jeffrey A. Engelman, M.D., Ph.D., Lecia V. Sequist, M.D., M.P.H., WeiWei Tan, Ph.D., Leena Gandhi, M.D., Ph.D., Mari Mino-Kenudson, M.D., Greg C. Wei, Ph.D., S. Martin Shreeve, M.D., Ph.D., Mark J. Ratain, M.D., Jeffrey Settleman, Ph.D., James G. Christensen, Ph.D., Daniel A. Haber, M.D., Ph.D., Keith Wilner, Ph.D., Ravi Salgia, M.D., Ph.D., Geoffrey I. Shapiro, M.D., Ph.D., Jeffrey W. Clark, M.D., and A. John Iafrate, M.D., Ph.D.1-3 Such findings claim that patients’ outcomes could be optimized by tests tumors for particular mutated pathways and directing therapies against those mutant pathways.